2026 SIU Congress | Professor Jeremy Teoh: Bringing Asian Urology to the Global Stage Through High-Quality Research and International Collaboration

2026 SIU Congress | Professor Jeremy Teoh: Bringing Asian Urology to the Global Stage Through High-Quality Research and International Collaboration

The 46th Annual Congress of the Société Internationale d'Urologie (SIU) was held in Florence, Italy, from November 11 to 14, 2026. On this occasion, Oncology Frontier – UroStream invited Professor Jeremy Yuen Chun Teoh of the Faculty of Medicine, The Chinese University of Hong Kong, Chair of the Organizing Committee of this year's congress, to share his insights on the overall congress program, the development of Asian urology and its pathway toward greater international academic collaboration, as well as his motivation and vision for running for the position of SIU General Secretary-elect.
Professor Darren Poon: Optimizing Perioperative Bladder Cancer Care and Advancing Collaboration in Asia

Professor Darren Poon: Optimizing Perioperative Bladder Cancer Care and Advancing Collaboration in Asia

At the European Society for Medical Oncology (ESMO) Congress 2026, perioperative treatment for bladder cancer remained a key focus. How systemic therapies can be integrated with surgery, while balancing efficacy, cumulative toxicity and treatment burden, is an important clinical question. In this interview with Oncology Outlook · Urology Times, Professor Darren Poon discusses the implications of VOLGA, the potential impact on practice in Hong Kong, China, and his expectations for the inaugural ESMO Genitourinary Cancers Asia congress in 2027.
Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

Professor Yige Bao: Exploring a New Perioperative Treatment Pathway for High-Risk Upper Tract Urothelial Carcinoma — Rationale, Interim Results, and Future Directions of the WUTSUP-02 Study

At the 2026 European Society for Medical Oncology (ESMO) Congress, the Department of Urology at West China Hospital of Sichuan University reported interim results from the WUTSUP-02 study, which explored the value of neoadjuvant treatment with disitamab vedotin plus tislelizumab, followed by surgery and adjuvant tislelizumab, in patients with high-risk upper tract urothelial carcinoma (UTUC). Addressing the limited perioperative treatment options for this patient population, Professor Yige Bao of West China Hospital of Sichuan University discusses the rationale behind the WUTSUP-02 study, its interim efficacy findings, and future directions for patient selection and evidence generation.
ESMO 2026 | Professor Jiwei Huang: Exploring Personalized Treatment for Non-Clear Cell Renal Cell Carcinoma Through Targeted Therapy Plus Immunotherapy—The Clinical Rationale, Efficacy Signals, and Identification of Benefiting Patient Populations in the FRONTIER Study

ESMO 2026 | Professor Jiwei Huang: Exploring Personalized Treatment for Non-Clear Cell Renal Cell Carcinoma Through Targeted Therapy Plus Immunotherapy—The Clinical Rationale, Efficacy Signals, and Identification of Benefiting Patient Populations in the FRONTIER Study

During the 2026 European Society for Medical Oncology (ESMO) Congress, updated results from the FRONTIER study exploring first-line fruquintinib plus serplulimab in non-clear cell renal cell carcinoma were presented. Non-clear cell renal cell carcinoma encompasses multiple pathological subtypes with substantial differences in biological behavior and molecular characteristics, and the available treatment evidence remains limited. Oncology Frontier – UroStream invited Professor Jiwei Huang from Renji Hospital, Shanghai Jiao Tong University School of Medicine, to discuss the rationale behind the study design, updated efficacy data, and biomarker investigations, providing insights into research directions for personalized treatment of non-clear cell renal cell carcinoma.
Professor Zhenhua Liu: Exploring the Potential of PSMA-Targeted ADCs in Advanced Prostate Cancer — From Early SHR-4394 Findings and Patient Selection to Combination Therapy Strategies

Professor Zhenhua Liu: Exploring the Potential of PSMA-Targeted ADCs in Advanced Prostate Cancer — From Early SHR-4394 Findings and Patient Selection to Combination Therapy Strategies

Patients with advanced prostate cancer whose disease continues to progress despite multiple lines of treatment urgently need new therapeutic options. At the 2026 European Society for Medical Oncology (ESMO) Congress, the Phase I study of SHR-4394, an antibody–drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), attracted considerable attention. Oncology Frontier – UroStream invited Professor Zhenhua Liu of West China Hospital, Sichuan University, to discuss the clinical needs addressed by this study, patient selection, safety and preliminary antitumor activity, as well as future directions in drug design and combination therapy.
Professor Alberto Briganti: Evaluating the Value of Perioperative Intensification Against Surgery Alone — Study Design, Pathological Findings, and Patient Selection in the PROTEUS Subgroup Analysis

Professor Alberto Briganti: Evaluating the Value of Perioperative Intensification Against Surgery Alone — Study Design, Pathological Findings, and Patient Selection in the PROTEUS Subgroup Analysis

For patients with high-risk localized or locally advanced prostate cancer who are candidates for surgery, the clinical value of perioperative treatment intensification compared with surgery alone, as well as the identification of patients most likely to benefit, remain central questions in current clinical research. At the 2026 European Society for Medical Oncology (ESMO) Congress, the PROTEUS subgroup analysis reported a direct comparison of perioperative apalutamide plus androgen deprivation therapy (ADT) followed by surgery versus surgery alone. Oncology Frontier – UroStream invited the study presenter, Professor Alberto Briganti of Vita-Salute San Raffaele University in Milan, Italy, to discuss the study design, pathological findings, and their potential relationship with long-term outcomes, as well as how further subgroup analyses and biomarker assessments may help identify patients most likely to benefit from treatment intensification.
ESMO 2026 | Blanca Homet Moreno: New Evidence and Key Questions in Bladder Cancer Treatment — Perioperative Therapy, Patient Selection for Bladder Preservation, and Prospects for ADC-Based Combinations

ESMO 2026 | Blanca Homet Moreno: New Evidence and Key Questions in Bladder Cancer Treatment — Perioperative Therapy, Patient Selection for Bladder Preservation, and Prospects for ADC-Based Combinations

The 2026 European Society for Medical Oncology (ESMO) Congress presented findings from several studies in genitourinary cancers. Among the key topics were differences in the results of studies investigating perioperative chemotherapy combined with immunotherapy, patient selection for bladder-preserving treatment, and emerging approaches combining antibody–drug conjugates (ADCs) with immunotherapy. These developments raise important questions for bladder cancer treatment. How should new evidence influence established clinical perspectives? As treatment options continue to expand, how can clinicians better define individualized treatment pathways for patients? Oncology Frontier – UroStream invited Blanca Homet Moreno, a researcher in the oncology division of Merck & Co., for an interview to share her observations and perspectives on these topics.